CAS: 140148-70-5; (S)-1-Boc-Pyrrolidine-3-Carboxylic Acid

相似化合物

59378-75-5 72925-16-7 72580-53-1

上下游产品

CAS号1099646-61-3 S-吡咯烷-3-羧酸甲酯盐酸盐 | CAS号313706-15-9 (S)-1-B°C-3-羧基吡咯烷甲酯 | CAS号224168-68-7 3(S)-碘甲基吡咯烷-1-羧酸叔丁酯 | CAS号1374673-89-8 (3S)-3-乙酰基吡咯烷-1... | CAS号199174-24-8 (S)-1-B°C-3-羟甲基吡咯烷 | CAS号1251570-88-3 (S)-3-((s)-1-羟基... | CAS号1251570-77-0 (S)-3-(3-甲基丁酰基)...

1-Boc-吡咯烷-3-甲酸甲酯置于水,Potassium Carbonate,Lithium Hydroxide体系中,用 四氢呋喃,Aq. Phosphate Buffer 用作溶剂,化学反应生成(S)-1-Boc-吡咯烷-3-甲酸
参考文献:Discovery Of A Potent,Dual Serotonin And Norepinephrine Reuptake Inhibitor
标题:Discovery Of A Potent,Dual Serotonin And Norepinephrine Reuptake Inhibitor
摘要:The Objective Of The Described Research Effort Was To Identify Novel Serotonin And Norepinephrine Reuptake Inhibitor (Snri) With Improved Norepinephrine Transporter Activity And Acceptable Metabolic Stability And Exhibiting Minimal Drug-Drug Interaction. We Describe Herein The Discovery Of A Series Of 3-Substituted Pyrrolidines Exemplified By Compound 1. Compound 1 Is A Selective Snri In Vitro And In Vivo Has Favorable Adme Properties,And Retains Inhibitory Activity In The Formalin Model Of Pain Behavior. Compound 1 Thus Represents A Potential New Probe To Explore Utility Of Snris In Central Nervous System Disorders,Including,Chronic: Pain Conditions.
Doi:10.1021/ml400049P

专利信息

专利号:EP-1836163-B1
优先权日:2004-12-23
标题 :Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin
发明人：BREITENSTEIN WERNER; COTTENS SYLVAIN; EHRHARDT CLAUS; JACOBY EDGAR; LORTHIOIS EDWIGE LILIANE JEANNE; MAIBAUM JUERGEN KLAUS; OSTERMANN NILS; SELLNER HOLGER; SIMIC OLIVER
权利人:NOVARTIS AG
摘要:Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula I wherein the substituents are as described in the specification.